Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
11 August 2000Website:
http://cgen.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 69 min agoDividend
Analysts recommendations
Institutional Ownership
CGEN Latest News
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipeline Compugen to receive $5 million milestone payment from AstraZeneca HOLON, Israel , May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody.
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago.
Compugen Ltd. (NASDAQ:CGEN ) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO Alberto Sessa - CFO Eran Ophir - CSO Michelle Mahler - CMO Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
Compugen Ltd. announced the online publication of a peer-reviewed paper titled "PVRIG is expressed on stem-like T cells in dendritic cell-rich niches in tumors and its blockade may induce immune infiltration in non-inflamed tumors" in Cancer Immunology Research, a journal of the American Association for Cancer Research.
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compugen Ltd. (NASDAQ:CGEN ) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
What type of business is Compugen?
Compugen Ltd. is an Israeli company specializing in therapeutic discoveries and developments. It was registered in Israel in 1993. The company's main focus is on discovering new drugs and developing therapeutic agents in the field of cancer immunotherapy. The innovative immuno-oncology program consists of three clinical-stage programs targeting immune checkpoints: COM701, BAY 1905254, and COM902. COM701 is a first-in-class antibody for the treatment of solid tumors, being clinically developed in collaboration with BMS (Bristol-Myers Squibb). BAY 1905254 has demonstrated anti-tumor activity as a monotherapy, and it also has additional anti-tumor activity in combination with other cancer therapy approaches, indicating the possibility of multiple combined uses in cancer immunotherapy. COM902 is a therapeutic antibody being developed for patients with advanced malignant neoplasms.
What sector is Compugen in?
Compugen is in the Healthcare sector
What industry is Compugen in?
Compugen is in the Biotechnology industry
What country is Compugen from?
Compugen is headquartered in Israel
When did Compugen go public?
Compugen initial public offering (IPO) was on 11 August 2000
What is Compugen website?
https://cgen.com
Is Compugen in the S&P 500?
No, Compugen is not included in the S&P 500 index
Is Compugen in the NASDAQ 100?
No, Compugen is not included in the NASDAQ 100 index
Is Compugen in the Dow Jones?
No, Compugen is not included in the Dow Jones index
When does Compugen report earnings?
Next earnings report date is not announced yet